文献速递生殖医学

重复剂量GnRH激动剂用于黄体支持:一项概念验证研究

Repeated GnRH agonist doses for luteal support: a proof of concept.
PubMed 文献 · Reprod Biomed Online · 2019-07-23

这项前瞻性试验在GnRH激动剂触发排卵的IVF周期中,对雌二醇超过2500 pg/ml的患者随机给予GnRH激动剂黄体支持(0.1 mg皮下注射隔日一次,胚胎移植后第3天开始)或对照组给予80 µg重组人绒毛膜促性腺激素(HCG)支持。因2例卵巢过度刺激综合征(OHSS)停止HCG组随机化,仅继续GnRH激动剂支持。GnRH激动剂组39例无OHSS,临床妊娠率43.6%。

要点

  • GnRH激动剂黄体支持组39例,HCG微剂量组7例,GnRH激动剂组无OHSS发生。
  • GnRH激动剂黄体支持临床妊娠率43.6%。
  • GnRH激动剂支持后LH和孕酮浓度上升。

核心结论

  • 隔日重复剂量GnRH激动剂黄体支持为GnRH拮抗剂IVF周期中经GnRH激动剂触发排卵的女性提供了安全有效的黄体支持。

研究设计与样本

  • 前瞻性试验,纳入GnRH激动剂触发排卵后雌二醇超过2500 pg/ml的患者,随机分为GnRH激动剂黄体支持组(0.1 mg皮下注射隔日一次,胚胎移植后第3天开始)或对照组(胚胎移植后第3天给予80 µg重组人HCG)。
  • 因2例OHSS停止HCG黄体支持随机化,研究仅继续GnRH激动剂黄体支持。
  • GnRH激动剂黄体支持组39例,HCG微剂量组7例,所有患者均行第5天囊胚移植。

主要发现

  • GnRH激动剂支持组无OHSS病例,无其他不良事件记录。
  • 妊娠试验前无出血病例,因此无黄体功能不足病例。
  • GnRH激动剂黄体支持的临床妊娠率为43.6%。
  • 刺激周期中激素动态反映引入GnRH激动剂支持后LH和孕酮浓度上升。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: What are the safety and feasibility of repeated subcutaneous doses of gonadotrophin-releasing hormone (GnRH) agonist for luteal support in IVF cycles triggered by a GnRH agonist? DESIGN: In this prospective trial, patients exhibiting oestradiol concentrations of over 2500 pg/ml after use of a GnRH agonist for triggering ovulation were initially randomized to GnRH agonist luteal support (0.1 mg subcutaneously every other day, starting on day 3 after embryo transfer) or to a control group supported by 80 µg of recombinant human chorionic gonadotrophin (HCG) on day 3 after embryo transfer. All patients underwent a day 5 blastocyst transfer. Randomization to the HCG luteal support was stopped owing to two cases of ovarian hyperstimulation syndrome (OHSS) and the study was continued solely with GnRH agonist luteal support. RESULTS: The study included 39 women in the repeated GnRH agonist luteal support group and seven in the HCG micro dose group. There were no cases of OHSS among patients supported by a GnRH agonist, and no other adverse events were recorded. There were no cases of bleeding before the pregnancy test, and hence no cases of an insufficient luteal phase. A clinical pregnancy rate of 43.6% was achieved with GnRH agonist luteal support. Hormone dynamics during the stimulation cycle reflected rising LH and progesterone concentrations after the introduction of GnRH agonist support. CONCLUSIONS: Repeated doses of GnRH agonist every other day as a method of luteal support provided safe and effective luteal support for women who underwent GnRH agonist triggering in a GnRH antagonist IVF cycle.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Wiser A, Klement AH, Shavit T, et al. Repeated GnRH agonist doses for luteal support: a proof of concept. Reprod Biomed Online. 2019. PMID: 31628035. doi:10.1016/j.rbmo.2019.07.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。